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Abstract (228 words) 
Background: 
During the post discharge phase following a heart failure hospitalisation (HFH), patients are 
at high risk of early readmission despite standard of care therapy. We examined the impact of 
chronic exposure to ivabradine on early readmissions in patients hospitalised for heart failure 
during the course of the SHIFT study (Systolic Heart Failure treatment with the If inhibitor 
ivabradine Trial). 
Methods and results: 
1186 of the 6505 randomised patients experienced at least one HFH during the study, and 
were more severe than those without HFH. Of these 1186 patients, 334 patients (28%) were 
rehospitalised within 3 months for any reason, mostly for cardiovascular causes (86%), 
including HFH (61%).  Ivabradine was associated with fewer all-cause hospitalisations at one 
month (incidence rate ratio (IRR): 0.70, 95% CI 0.50 to 1.00 p<0.05), 2 months (IRR 0.75, 
95% CI 0.58 to 0.98, p=0.03), and 3 months (IRR 0.79, 95% CI 0.63 to 0.99, p=0.04). A trend 
for a reduction in cardiovascular and HF hospitalisations was also observed in ivabradine-
treated patients. 
Conclusion: 
We demonstrate in this post hoc analysis that chronic exposure to ivabradine reduces the 
incidence of all cause hospitalisations during the vulnerable phase after a HFH. Further 
studies are needed to investigate if in-hospital or early post discharge initiation of ivabradine 
could be useful to improve early outcomes in patients hospitalised for HF. 
 
Keywords: Ivabradine; hospitalisations; heart failure; outcomes; vulnerable phase. 
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Introduction 
The number of hospitalisations for heart failure remains high in many European countries, 
representing 1-2% of all hospital admissions.1 In comparison to outpatients with chronic heart 
failure, patients hospitalised for heart failure have high rates of readmission. A recent 
European registry reports a rate of 1-year hospitalisation as high as 44% after discharge, 
versus 32% in outpatients.2 These alarming figures have a considerable impact on both 
healthcare cost and prognosis. Patients hospitalised for heart failure are particularly at risk for 
death or rehospitalisation in the first weeks following discharge, while risk decreases 
significantly after 3 to 6 months.3-5 In Europe, 3 months after discharge, a quarter of patients 
had been rehospitalised, and 13.5% had died.6 This immediate post discharge period has been 
referred as the “vulnerable phase”.7  
Patients with heart failure often present with multiple comorbidities, which put them at a 
higher risk for recurrent hospitalisations, whatever the cause.8 The need for an effective 
treatment reducing the global burden of rehospitalisation -whether of cardiac or non-cardiac 
causes- is crucial. In SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine 
Trial), heart rate reduction with ivabradine was associated with a 26% risk reduction of first 
heart failure hospitalisation, and 11% risk reduction of first all-cause hospitalisation.9 
 
Since reducing the burden of rehospitalisations during the vulnerable phase is of critical 
clinical importance, we analyse here the effect of chronic exposure to  ivabradine versus 
placebo on all-cause recurrent hospitalisations occurring up to 3 months after a hospitalisation 
for worsening heart failure in the SHIFT trial. 
 
Methods 
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The complete design and results of the SHIFT trial have been previously reported.9,10 Briefly, 
SHIFT was a randomised, double-blind, placebo-controlled trial in outpatients with 
symptomatic and stable heart failure (≥4 weeks), systolic dysfunction (left ventricular ejection 
fraction ≤35%), heart rate ≥70 bpm, and in sinus rhythm. All subjects had been hospitalised 
for worsening heart failure in the year before inclusion. In total, 6505 patients treated with 
guideline-recommended therapy were randomised to placebo or ivabradine (starting dose 5 
mg bid, titrated to 7.5 mg or 2.5 mg bid, according to heart rate and tolerability). The primary 
study endpoint was a composite of cardiovascular mortality or hospitalisation for worsening 
heart failure. Secondary endpoints included both individual components of the composite 
endpoint, all-cause mortality, heart failure mortality, and all-cause hospitalisation, among 
others. All hospitalisations were adjudicated by an endpoint validation committee. Diagnosis 
of heart failure as a main reason for hospitalisation had to be confirmed. 
 
In the present study, we identified SHIFT patients who had had at least one heart failure 
hospitalisation during the trial, and analysed events subsequent to that hospitalisation during 
the vulnerable phase. This vulnerable phase was defined as the 3 months after the date of 
admission for a first hospitalisation due to worsening heart failure, and, thus, includes the 
period of hospitalisation. In this population, the median duration of hospitalisation was 8 days. 
We considered the total number of events that occurred during a selected timeframe (1, 2, and 
3 months) after the first admission for worsening heart failure. Readmissions after a heart 
failure hospitalisation are known to be driven by both cardiac and non-cardiac causes.4 Thus 
our analysis focuses on all-cause rehospitalisations. Hospitalisations due to cardiovascular 
cause or due to heart failure are also described. 
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This study is a post hoc analysis of SHIFT data. Therefore, statistical methods and 
analysed population were selected a posteriori. Disposition of the population was described by 
counting the number of patients with a recurring event during the vulnerable phase for each 
treatment group. Baseline characteristics are shown as means±standard deviations (SD) for 
continuous variables, and numbers and percentages for categorical variables. Baseline 
characteristics of patients with at least one heart failure hospitalisation during the study were 
compared with those of patients who had no heart failure hospitalisation. Comparison was 
done in the pooled treatment groups, using a Kruskal-Wallis test for continuous variables and 
χ2 test for categorical variables. In addition, we present the baseline characteristics of patients 
rehospitalised for any cause within 3 months after the first heart failure hospitalisation. 
Treatment effect between ivabradine and placebo groups was measured as the incidence rate 
ratio (IRR) for recurrent hospitalisations during the vulnerable phase (all-cause, due to 
cardiovascular cause, or due to heart failure). Each IRR was calculated using a Poisson 
regression model (with correction for overdispersion), with censoring time at 1, 2, and 3 
months after the first hospital admission for worsening heart failure. In addition, IRRs were 
adjusted for the following prognostic factors at baseline: beta-blocker intake (also used as a 
stratification factor for randomisation); New York Heart Association (NYHA) class; 
ischaemic cause of heart failure; age; systolic blood pressure; heart rate; left ventricular 
ejection fraction; and glomerular filtration rate, estimated using the Modification in Diet in 
Renal Disease equation.11 Associated 95% confidence intervals (CI) and p values (two-sided 
test) are presented, with a p value <0.05 considered as significant. The cumulative incidence 
rate of all-cause rehospitalisations was plotted across time for each treatment group, using the 
Nelson-Aalen’s estimator. Death rates were calculated at 1, 2 and 3 months after the first 
hospital admission for worsening heart failure in both ivabradine and placebo groups. SAS 
(statistical analysis system) version 9.1 and R version 2.14.0 were used for analyses. 
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Results 
In total, 1186 of the 6505 randomised patients experienced at least one hospitalisation for 
heart failure during the study.  The breakdown of participants and events in this population is 
presented in Figure 1. A total of 334 patients (28%) were rehospitalised within 3 months for 
any reason (131 [25%] in the ivabradine group, and 203 [30%] in placebo). The reasons for 
rehospitalisations were cardiovascular for 286 (86%) patients (109 [83%] ivabradine, 177 
[87%] placebo), and worsening heart failure for 204 (61%) patients (78 [60%] ivabradine, 126 
[62%] placebo). A total of 85 patients experienced at least two recurrent hospitalisations for 
any cause after the first heart failure hospitalisation during the study (27 ivabradine, 58 
placebo). Of these, 53 had at least two recurrent hospitalisations due to cardiovascular cause 
(16 ivabradine, 37 placebo), and 27 due to heart failure cause (7 ivabradine, 20 placebo). 
 
Baseline characteristics of patients who had at least one hospitalisation for heart failure 
during the study were compared with those who had no heart failure hospitalisation (Table 1). 
Overall, the two groups of patients differed significantly in many respects. As compared with 
patients with no heart failure readmission, those who had at least one heart failure 
hospitalisation were more likely to be older, to have a higher heart rate, a lower blood 
pressure, a lower left ventricular ejection fraction, a lower glomerular filtration rate , and were 
more likely to be in NYHA class III or IV. As regards their medical history, hospitalised 
patients had a longer duration of heart failure, and were more likely to have renal failure, 
diabetes, atrial fibrillation and/or flutter, and to have had a history of stroke. Both groups of 
patients also differed in terms of their concomitant treatments: patients hospitalised for heart 
failure during the study were more likely to be treated with mineralocorticoid receptor 
antagonists, other diuretics, and digitalis at baseline as compared with patients who had no 
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heart failure rehospitalisation. On the other hand, patients hospitalised for heart failure during 
the study were less likely to be prescribed beta-blockers or angiotensin-converting enzyme 
(ACE) inhibitors at baseline, and fewer patients were receiving ≥50% of target dose of beta-
blocker as compared with patients who had no heart failure admission.  
 
The 334 patients rehospitalised for any cause within 3 months after the first heart failure 
hospitalisation had similar baseline characteristics as compared with all patients who had an 
hospitalisation for heart failure during the study, with the exception of the dose of beta-
blockers at randomisation: fewer (39%) patients rehospitalised within 3 months were 
receiving ≥50% of target dose, versus 47% of all patients hospitalised for heart failure (Table 
1).  
 
Cumulative incidence of all-cause hospitalisations was lower in the ivabradine group as 
compared with the placebo group over the 3 months after a first hospital admission for 
worsening heart failure (Figure 2). Accordingly, ivabradine was associated with fewer total 
all-cause hospitalisations as compared with placebo at 1 month (54 events with ivabradine 
versus 102 events with placebo, IRR 0.70, 95% CI 0.50 to 1.00, p<0.05), 2 months (115 
versus 201 events, IRR 0.75, 95% CI 0.58 to 0.98, p=0.03), and 3 months (166 versus 278 
events, IRR 0.79, 95% CI 0.63 to 0.99, p=0.04) after the first heart failure hospitalisation.  
 
As regards the other endpoints, there was a trend towards reduction in the recurrence of 
hospitalisations due to cardiovascular causes in the ivabradine group as compared with 
placebo at 1 month (38 versus 76 events, IRR 0.66, 95% CI 0.44 to 1.01, p=0.05), 2 months 
(90 versus 155 events, IRR 0.77, 95% CI 0.57 to 1.02, p=0.07) and 3 months (131 versus 221 
events, IRR 0.79, 95% CI 0.62 to 1.01, p=0.06) after the first heart failure hospital admission 
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event (Table 2). A similar pattern of effect was identified for rehospitalisations due to heart 
failure at 1 month (21 versus 42 events, IRR 0.67, 95% CI 0.40 to 1.13, p=0.13), 2 months (56 
versus 97 events, IRR 0.77, 95% CI 0.55 to 1.09, p=0.14), and 3 months (86 versus 148 
events, IRR 0.78, 95% CI 0.59 to 1.02, p=0.07). Death rates were similar in both treatment 
groups at 1 month (8% with ivabradine versus 9% with placebo), 2 months (11% versus 12%), 
and 3 months (13% versus 14%) after the first heart failure hospitalisation. 
 
Discussion 
Our analysis showed that patients hospitalised for heart failure during the study were more 
severe as compared with their counterparts who had no heart failure hospitalisation with 
respect to clinical status, cardiac function, and comorbidities. In line with the more severe HF 
profile, these patients had more concomitant treatment with diuretics, digitalis, and 
mineralocorticoid receptor antagonists. Moreover, patients hospitalised for heart failure who 
had been randomised to ivabradine had a lower incidence of early recurrent hospitalisations 
following a first heart failure hospitalisation during the trial than those on placebo. This 
reduction of risk was significant when considering all-cause rehospitalisations, and ranged 
from 21% to 30% within the first 3 months after a first event of heart failure hospitalisation. A 
consistent trend for reduction in the same range of magnitude (from 21% to 34%) was 
observed for both cardiovascular and heart failure rehospitalisations. The favourable effect of 
ivabradine on early readmissions was unlikely to be influenced by a difference in death rates, 
as these were similar between the two groups. 
 
Some data support the importance of early initiation of recommended heart failure 
therapies. One trial compared the effect of an in-hospital initiation of carvedilol with a later 
initiation of carvedilol performed in an outpatient setting.12 This trial was not powered to 
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assess the impact of the timing of beta-blockers initiation on outcome. However, it 
demonstrated that in-hospital initiation of carvedilol was associated with its higher use 90 
days after discharge, supporting importance of early introduction of heart failure 
recommended therapies. Data from  a registry similarly suggest that use of beta-blockers at 
hospital discharge was associated with better prognosis.13 A propensity score analysis 
suggested that discharge use of ACE inhibitor was associated with improvement of 
prognosis.14 A recent post hoc analysis from the Eplerenone in Mild Patients Hospitalization 
and Survival Study in Heart Failure (EMPHASIS-HF) trial demonstrated that eplerenone 
prevents readmission when initiated soon after a cardiovascular hospitalisation in patients 
with systolic heart failure and mild symptoms.15 Only a few randomised clinical trials have 
explored the effect of treatment during the vulnerable phase after hospitalised heart failure, by 
analysing outcomes early post discharge.16-20 In a randomised phase 2 clinical trial, tolvaptan 
did not demonstrate differences in worsening heart failure at 60 days compared with 
placebo.16 However, in a post hoc analysis, 60 day mortality was lower in tolvaptan-treated 
patients with renal dysfunction or severe systemic congestion. In the Acute Study of Clinical 
Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, nesiritide 
had no effect on rehospitalisation or death within 30 days compared with placebo.17 
Treatment of acute heart failure with the intravenous vasodilator serelaxin was associated 
with fewer deaths at day 180 although this was a post hoc analysis.19 Finally, the Aliskiren 
Trial on Acute Heart Failure Outcomes (ASTRONAUT) demonstrated that in hospitalized 
patients with heart failure, the initiation of the direct renin inhibitor aliskiren in addition to 
standard therapy did not reduce cardiovascular death or heart failure hospitalisation at 6 and 
12 month after discharge.20 
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We acknowledge the fact that our current analysis included patients who were chronically 
exposed to ivabradine from the time of randomisation and who experienced a first heart 
failure admission. In a previous analysis, we demonstrated that ivabradine reduced the total 
burden of heart failure hospitalisations by 25% during the full duration of the study (22.9 
months).21 We here further extend our analysis  by showing that this beneficial effect is 
observed during the high risk early post discharge vulnerable phase and applies to all-cause 
hospitalisations. 
 
Prescription of standard heart failure treatment at discharge could help to mitigate 
immediate post discharge outcomes. This is supported by data of heart failure cohorts, where 
use of beta-blockers, ACE inhibitors, and angiotensin receptor blockers (ARBs) were 
associated with a lower rate of readmission and/or mortality up to 90 days after discharge.22-24 
Accordingly, ESC guidelines recommend the initiation of evidence-based therapy as soon as 
patients are stabilised after a hospitalisation for heart failure.25 The early introduction of 
treatments is critical, as patients not optimally managed at the time of discharge are often left 
untreated at a later stage. However, despite these recommendations, prescription rates of beta-
blockers, ACE inhibitors and ARBs remain insufficient, especially in patients at highest 
risk.26 This is in line with the results of our analysis, which showed that patients with a more 
severe profile had a lower prescription rate of beta-blockers and ACE inhibitors than less 
severe patients. One of the obstacles limiting the early prescription or uptitration of standard 
care therapy after a heart failure hospitalisation is linked to the adverse effects of these drugs 
on blood pressure, in a period during which the haemodynamic status of patients is still 
unstable. Unlike beta-blockers, ivabradine is devoid of a negative inotropic effect. In addition, 
ivabradine does not share the blood pressure–lowering effects of beta-blockers, ACE 
inhibitors, and ARBs. This suggests that ivabradine might be a relatively manageable 
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treatment without undesired incremental collateral effects in the days or weeks following a 
heart failure hospitalisation. This is in line with the observations of a recent pilot trial in 
patients with decompensated heart failure in whom ivabradine appeared to be well tolerated 
with no haemodynamic deterioration when used in acutely ill patients.27 
 
The exact mechanism underlying the beneficial effects of ivabradine suggested by our 
analysis during the vulnerable period after an episode of worsening heart failure remains to be 
elucidated. At discharge, elevated heart rate occurs in a large proportion of patients,28 and is 
associated with an increased risk of death and rehospitalisation in the early post discharge 
period.29-31 In a cohort study of heart failure patients with heart rate ≥75 bpm at discharge, 
each 10-bpm increment was associated with an increase of 30% in risk of all-cause death, and 
13% in risk of rehospitalisations during the 30-day period following hospital discharge.30 
Outside this window, the correlation between high heart rate at discharge and worse outcome 
was lessened (16% increased risk for all-cause death per 10-bpm increment; and no increase 
in risk for all-cause rehospitalisations). These data are in agreement with the favourable effect 
of heart rate reduction with ivabradine on early outcomes observed in our study. Decreasing 
heart rate with ivabradine at discharge may improve myocardial energetics and oxygen 
consumption, and reduce total afterload,32 thereby lessening the risk of relapse after hospital 
discharge. Recent data from the OPTIMIZE-HF (Organized Program To Initiate lifesaving 
treatMent In hospitaliZed patients with heart failure) registry found that a large proportion of 
heart failure patients (71%) had a heart rate ≥70 bpm at hospital discharge, despite being 
treated with beta-blockers. Overall, the authors estimated that approximately 40% of 
hospitalised patients for heart failure could qualify for initiation of ivabradine at time of 
discharge.28  
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The reduction in readmissions in the ivabradine group was observed as early as 1 month 
after first hospitalisation. This early effect is in line with the immediate improvement in 
haemodynamic parameters (increase in stroke volume with maintained cardiac output) 
observed after an acute administration of ivabradine in heart failure patients with severely 
depressed left ventricular function.33  This rapid stabilising effect is further supported by the 
short-term reduction in N-terminal pro-brain natriuretic peptide and improvement in NYHA 
class provided by ivabradine, which were achieved after only 3 months of treatment on top of 
standard care in heart failure patients.34  Similar findings were reported in a separate study 
after just 4 months of treatment with ivabradine.35 Altogether, these data suggest that patients 
chronically treated with ivabradine could rapidly stabilise patients after a hospitalisation for 
heart failure, by preventing degradation of left ventricular function and clinical status. 
However our current analysis does not provide information on the potential benefit of in-
hospital or early post discharge initiation of ivabradine since patients were exposed to the 
drug from the randomisation. 
 
There are some limitations to our analysis. The present data are based on a post hoc 
analysis of a trial including chronic, stable heart failure patients, and the original study was 
not designed to investigate the effect of treatment in patients hospitalised for heart failure. 
Therefore, we cannot assess the respective role of exposure to ivabradine before versus after 
hospitalisation in the observed effects on early readmissions. IRR were adjusted using 
prognostic factors which may no longer be representative of the patient’s risk, as they were 
collected at the time of inclusion in the SHIFT study, and not at the time of the first HF 
hospitalisation during the study. On the other hand, this is the first analysis that describes the 
effect of a treatment on repeated hospitalisation during the critical 3 month-period after a 
hospitalisation for heart failure. Our analysis is based on the date of hospitalisation for heart 
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failure, which, in contrast to the date of discharge, was adjudicated in SHIFT, and thus more 
reliable. However, the statistical method does not take into account the treatment effect on the 
first heart failure hospitalisation, which had been shown to be reduced by ivabradine.9 This 
might have produced an imbalance between the placebo and ivabradine groups, and does not 
preserve the randomisation planned in the original design. Although a beneficial trend in 
favour of ivabradine was observed on heart failure and on cardiovascular rehospitalisations, 
this did not reach a significant threshold. This may be due to the limited number of events 
observed here and therefore a lack of power. It should however be noticed that the vast 
majority (86%) of all-cause rehospitalisations during the vulnerable phase was due to 
cardiovascular cause, and 61% were due to heart failure. 
 
Conclusion 
Development of new therapeutic strategies to prevent early recurrent hospitalisations is a 
major goal for heart failure management. Here, we demonstrated that chronic exposure to 
ivabradine is associated with a decrease in all-cause hospitalisation during the critical 3 
months after a hospitalisation for heart failure. Further studies are needed to investigate if in 
hospital or early post discharge initiation of ivabradine could be useful to improve early 
outcomes in hospitalised heart failure patients. 
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1186 patients with at least one hospitalisation for HF  
514 ivabradine 672 placebo 
131 patients rehospitalised  for any 
cause within 3 months after  first HF 
hospitalisation 
203 patients rehospitalised  for any 
cause within 3 months after  first HF 
hospitalisation 
104 had 1 rehospitalisation   
27 had 2 rehospitalisations 
109 patients for cardiovascular cause 
145 had 1 rehospitalisation   
58 had 2 rehospitalisations 
177 patients for cardiovascular cause 
126 patients for HF 78 patients for HF 
93 had 1 rehospitalisation   
16 had 2 rehospitalisations 
140 had 1 rehospitalisation   
37 had 2 rehospitalisations 
71 had 1 rehospitalisation   
7 had 2 rehospitalisations 
106 had 1 rehospitalisation   
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Table 1. Baseline characteristics of patients with a least one heart failure hospitalisation, 
patients rehospitalised for any cause within 3 months after the first heart failure 
hospitalisation, and patients with no heart failure hospitalisation during the SHIFT study. 
 At least one heart failure 
hospitalisation 
(n=1186) 
No hospitalisation 
for heart failure 
(n=5319) 
p-value* 
 
 All (n=1186) 
Readmission 
for any cause 
within 3 
months 
(n=334) 
  
Demographic characteristics     
Age (years) 62.2±11.5 62.1±12.0 60.0±11.3 <.0001 
Male 901 (76%) 263 (79%) 4069 (76%) 0.70 
Current smoker 191 (16%) 51 (15%) 927 (17%) 0.080 
Body mass index (kg/m2) 27.8±5.3 27.7±5.4 28.0±5.0 0.060 
Cardiac parameters     
Heart rate (bpm) 82.5±11.2 83.0±11.7 79.3± 9.2 <.0001 
Systolic blood pressure (mmHg) 119.0±16.7 118.5±17.9 122.3±15.7 <.0001 
Diastolic blood pressure 
 
74.3± 9.9 73.4±10.0 76.0±9.4 <.0001 
Left ventricular ejection fraction 
 
27.6±5.4 27.3±5.5 29.3± 5.0 <.0001 
NYHA class    <.0001 
Class II 445 (38%) 148 (44%) 2724 (51%)  
Class III 707 (60%) 178 (53%) 2516 (47%)  
Class IV 34 (3%) 8 (2%) 77 (1%)  
eGFR (mL/min/1.73m2) 69.8±23.6 
 
70.3±26.6 75.8±22.7 <.0001 
Medical history     
Duration of heart failure (years) 4.3±4.6 4.7±5.1 3.3±4.1 <.0001 
Ischemic cause of heart failure 813 (69%) 217 (65%) 3605 (68%) 0.61 
Coronary artery disease 869 (73%) 236 (71%) 3863 (73%) 0.65 
Myocardial infarction 680 (57%) 175 (52%) 2986 (56%) 0.45 
Renal failure 129 (11%) 39 (12%) 291 (5%) <.0001 
Hypertension 769 (65%) 200 (60%) 3545 (67%) 0.23 
Diabetes 427 (36%) 130 (39%) 1552 (29%) <.0001 
Stroke 125 (11%) 37 (11%) 398 (7%) 0.0005 
History of atrial fibrillation 
  
133 (11%) 36 (11%) 389 (7%) <.0001 
Treatment at randomisation     
Beta-blockers 1023 (86%) 279 (84%) 4797 (90%) <.0001 
≥50% target dose 473 (47%) 109 (39%) 2708 (58%) <.0001 
ACE inhibitors 900 (76%) 258 (77%) 4216 (79%) 0.0103 
ARB 186 (16%) 53 (16%) 741 (14%) 0.12 
Mineralocorticoid receptor 
 
824 (69%) 215 (64%) 3098 (58%) <.0001 
Diuretics 1079 (91%) 303 (91%) 4335 (82%) <.0001 
Digitalis 377 (32%) 107 (32%) 1039 (20%) <.0001 
Values are means±SD or numbers (%) of patients. *p-values comparing patients with at least one heart failure 
hospitalisation versus patients with no heart failure hospitalisation (Kruskal-Wallis test for continuous variables, 
or χ2 test for categorical variables). ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; 
eGFR=estimated glomerular filtration rate; NYHA=New York Heart Association. 
 
 Table 2. Incidence rate ratios for cardiovascular and heart failure hospitalisations up to 3 
months after a first hospitalisation for worsening heart failure during the SHIFT study. 
 
 Cumulative number of events Incidence rate ratio (95% CI) 
 
Ivabradine 
(N=514) 
Placebo 
(N=672) (adjusted for prognostic factors) 
Cardiovascular hospitalisations 
1 month 38 76 0.66 (0.44–1.01) 
2 months 90 155 0.77 (0.57–1.02) 
3 months 131 221 0.79 (0.62–1.01) 
Heart failure hospitalisations 
1 month 21 42 0.67 (0.40–1.13) 
2 months 56 97 0.77 (0.55–1.09) 
3 months 86 148 0.78 (0.59–1.02) 
 
Number of events corresponds to the total number of readmissions within the indicated timeframe after a first 
heart failure hospitalisation. CI=confidence interval. 
 
